Dithranol 0.1% in Zinc and Salicylic acid paste
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · 2000–2026
Showing the 50 most relevant studies, sorted by most relevant.
Dhirendra Kumar, Daniel F. Klessig
Molecular Plant-Microbe Interactions®, 2000
Luis A. J. Mur, Elena Prats, Sandra Pierre, et al.
Frontiers in Plant Science, 2013
N. Hoang, T. Thanh, Chanon Saengchan, et al.
The Plant Pathology Journal, 2025
Phytopathogen caused loss of global crop production of 16% and up to 25% in developing countries. Among them, fungi accounted for the highest ratio value with 42%, which direct reduced crop yield and quality. Nanotechnology can be applied to crop protection to build sustainable agricultural production. Polymers (gum, mucilage, chitosan) are naturally derived, readily available, inexpensive, convertible, and biodegradable, which could be combined with nanotechnology to enhance their properties and benefit. In this review, ionic gelation is more popular than nanoprecipitation, emulsion, γ-rays irradiation, and chemical reduction methods in preparing nanocomposites-based polymers in the management of fungal diseases in crop production. The chitosan was often dominated among the polymers. Moreover, the chitosan can be applied as chitosan nanoparticles or combined with an active ingredient (saponin, copper, silver, zinc, titanium dioxide, ethanolic blueberry extract, methanol of nanche extract, Mentha longifolia extract, Cymbopogon martinii essential oil, Harpin, salicylic acid, Thiamine, hexaconazole, dazomet, hexaconazole-dazomet) to enhance their efficacy in managing plant fungal disease. The fungicide, mental, and plant extracts are often loaded into the chitosan matrix to enhance antifungal and/or physical barrier properties. While phytohormones, vitamins, and mental are often used to stimulate plant disease resistance. And chitosan can be used as an adjuvant in metal/oxide mixture. In recent years, other polymers including polyethylene glycol, nanoliposomes, and poly(L-lactide) have been shown remarkable capabilities including resisting water washing and acting as a membrane filter with antifungal properties. These results show that the nanocomposites based-polymer has the ability to effectively manage plant diseases.
Abstract licence: CC BY-NC
Sailesh G. Gupta, Srichand G. Parasramani
International Journal of Research in Medical Sciences, 2025
M. Faizan, Shafaque Sehar, V. Rajput, et al.
Plants, 2021
J. Kong, Yuanjie Dong, Linlin Xu, et al.
Botanical Studies, 2014
Torsekar R, Gautam MM
2017
Topical therapy as monotherapy is useful in psoriasis patients with mild disease. Topical agents are also used as adjuvant for moderate-to-severe disease who are being concurrently treated with either ultraviolet light or systemic medications. Emollients are useful adjuncts to the treatment of psoriasis. Use of older topical agents such as anthralin and coal tar has declined over the years. However, they are cheaper and can still be used for the treatment of difficult psoriasis refractory to conventional treatment. Salicylic acid can be used in combination with other topical therapies such as topical corticosteroids (TCS) and calcineurin inhibitors for the treatment of thick limited plaques to increase the absorption of the latter into the psoriatic plaques. Low- to mid-potent TCS are used in facial/flexural psoriasis and high potent over palmoplantar/thick psoriasis lesions. The addition of noncorticosteroid treatment can also facilitate the avoidance of long-term daily TCS. Tacrolimus and pimecrolimus can be used for the treatment of facial and intertriginous psoriasis. Tazarotene is indicated for stable plaque psoriasis usually in combination with other therapies such as TCS. Vitamin D analogs alone in combination with TCS are useful in stable plaques over limbs and palmoplantar psoriasis. Topical therapies for scalp psoriasis include TCS, Vitamin D analogs, salicylic acid, coal tar, and anthralin in various formulations such as solutions, foams, and shampoos. TCS, vitamin D analogs, and tazarotene can be used in the treatment of nail psoriasis.
Abstract licence: CC BY-NC-SA
Jishma Panichikkal, Gopika Prathap, Remakanthan Appukuttan Nair, et al.
International Journal of Biological Macromolecules, 2021
R. Shemi, Rui Wang, E. Gheith, et al.
BMC Plant Biology, 2021
M. Berrocal-Lobo, Sophia L. Stone, Xin Yang, et al.
PLoS ONE, 2010
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.